Possible autoimmune hemolytic anemia induced by secukinumab: a case report

被引：1

作者：

Rahman, Perdana Aditya ^{[1
,2
]}

Kalim, Handono ^{[1
,2
]}

Prawitasari, Suci ^{[3
,4
]}

Raharjo, Fajar Maulana ^{[5
]}

机构：

[1] Univ Brawijaya, Rheumatol & Immunol Div, Dept Internal Med, Fac Med, Malang, Indonesia

[2] Saiful Anwar Gen Hosp, Rheumatol Immunol Div, Dept Internal Med, Malang, Indonesia

[3] Univ Brawijaya, Dept Dermatovenereol, Fac Med, Malang, Indonesia

[4] Saiful Anwar Gen Hosp, Dept Dermatovenereol, Malang, Indonesia

[5] Univ Brawijaya, Fac Med, Malang, Indonesia

来源：

PAN AFRICAN MEDICAL JOURNAL | 2022年 / 41卷

关键词：

Autoimmune hemolytic anemia; psoriasis; psoriatic arthritis; secukinumab; case report;

D O I：

10.11604/pamj.2022.41.41.32191

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

Secukinumab, an anti-IL-17 monoclonal antibody, has been used to treat psoriasis and psoriatic arthritis since 2015. Several adverse events were reported, such as diarrhea, upper respiratory tract infection, middle ear infection, and neutropenia. Here we report a probable case of autoimmune hemolytic anemia in a 39 years old male with psoriasis and psoriatic arthritis treated with secukinumab. Hemolytic anemia detected after first maintenance dose after completion of induction dose of secukinumab. The patient also had other comorbids, soft tissue infection that also predisposed to autoimmune hemolytic anemia, but secukinumab is still a possible etiology for drug-induced autoimmune hemolytic anemia based on Naranjo ' s score. The patient decided to continue secukinumab treatment, interestingly hemoglobin levels improved.

引用

页数：7

共 12 条

[1] Unexpected Hematologic Effects of Biotherapeutics in Nonclinical Species and in Humans [J].

Everds, Nancy E. ;

Tarrant, Jacqueline M. .

TOXICOLOGIC PATHOLOGY, 2013, 41 (02) :280-302

[2] Production of the effector cytokine interleukin-17, rather than interferon-γ, is more strongly associated with autoimmune hemolytic anemia [J].

Hall, Andrew M. ;

Zamzami, Omar M. ;

Whibley, Natasha ;

Hampsey, Daniel P. ;

Haggart, Anne M. ;

Vickers, Mark A. ;

Barker, Robert N. .

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2012, 97 (10) :1494-1500

[3] Guidelines on the management of drug-induced immune and secondary autoimmune, haemolytic anaemia [J].

Hill, Quentin A. ;

Stamps, Robert ;

Massey, Edwin ;

Grainger, John D. ;

Provan, Drew ;

Hill, Anita .

BRITISH JOURNAL OF HAEMATOLOGY, 2017, 177 (02) :208-220

[4]

Hwang Y, 2017, American Society of Hematology, V130, P3467

[5]

Krstic A, 2012, J BIOL REG HOMEOS AG, V26, P641

[6] Secukinumab: A New Treatment Option for Psoriatic Arthritis [J].

Mease P. ;

McInnes I.B. .

Rheumatology and Therapy, 2016, 3 (1) :5-29

[7] Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial [J].

Mease, Philip J. ;

Kavanaugh, Arthur ;

Reimold, Andreas ;

Tahir, Hasan ;

Rech, Juergen ;

Hall, Stephen ;

Geusens, Piet ;

Pellet, Pascale ;

Delicha, Evie Maria ;

Mpofu, Shephard ;

Pricop, Luminita .

RMD OPEN, 2018, 4 (02)

[8] Interleukin-17 and Its Implication in the Regulation of Differentiation and Function of Hematopoietic and Mesenchymal Stem Cells [J].

Mojsilovic, Slavko ;

Jaukovic, Aleksandra ;

Santibanez, Juan F. ;

Bugarski, Diana .

MEDIATORS OF INFLAMMATION, 2015, 2015

[9] A Review of the Use of Secukinumab for Psoriatic Arthritis [J].

Patel, Nupur U. ;

Vera, Nora C. ;

Shealy, Emily Rose ;

Wetzel, Margaret ;

Feldman, Steven R. .

RHEUMATOLOGY AND THERAPY, 2017, 4 (02) :233-246

[10]

Sebastien R, 2020, SECUKINUMAB INDUCED, V54, P933

← 1 2 →